1. A 78-year-old woman with type 2 diabetes is admitted with fever, rigors, and flank pain. Blood and urine cultures grow Escherichia coli. The susceptibility report shows the isolate is susceptible to ceftriaxone (zone diameter above the breakpoint on disk diffusion) but also susceptible to ertapenem and meropenem. The patient is hemodynamically stable but has two positive blood cultures. The intern proposes treating with ceftriaxone based on the susceptibility result. The attending asks whether the intern is comfortable with that plan given the clinical context. Which of the following best represents the evidence-based approach to definitive therapy for this patient?
A) Ceftriaxone is the preferred agent because the susceptibility result is definitive — disk diffusion is a validated methodology endorsed by CLSI and EUCAST, and any discordance between in vitro susceptibility and clinical outcomes in cephalosporin-treated ESBL bacteremia reflects host factors rather than a systematic limitation of cephalosporin activity against these organisms
B) Piperacillin-tazobactam is the preferred agent for ESBL-producing E. coli bacteremia because the beta-lactamase inhibitor tazobactam reliably suppresses ESBL enzyme activity at standard doses, producing clinical outcomes equivalent to carbapenems in randomized controlled trials for all severity levels of bloodstream infection
C) A carbapenem is the appropriate definitive therapy for this patient's ESBL-producing E. coli bacteremia; ESBL-producing organisms may appear susceptible to cephalosporins on routine disk diffusion due to inoculum effects that do not replicate in vivo conditions, and documented clinical failures with cephalosporins in ESBL-producing bacteremia support carbapenem use as definitive therapy for serious infections regardless of the reported in vitro cephalosporin susceptibility
D) The susceptibility result should be confirmed by broth microdilution MIC determination before any treatment decision is made; carbapenem therapy should be withheld until the MIC result is available, as initiating empiric carbapenem therapy before confirmation is a stewardship violation that contributes to carbapenem resistance selection
E) Fosfomycin or nitrofurantoin would be appropriate oral step-down agents for this patient's bacteremia once the patient is afebrile for 48 hours, because the urinary source means that urinary-concentrated agents achieve sufficient systemic exposure to eradicate the bacteremic focus in diabetic patients with uncomplicated presentations
ANSWER: C
Rationale:
Option C is correct. ESBL-producing organisms present a well-characterized laboratory pitfall: at the low standardized bacterial inocula used in disk diffusion testing, ESBL enzyme production may be insufficient to shift the zone diameter below the susceptibility breakpoint for cephalosporins, producing a falsely susceptible result. In actual infection — particularly bacteremia — the bacterial burden and local antibiotic concentrations create conditions where ESBL enzyme activity is more likely to reduce effective cephalosporin concentrations below the minimum inhibitory concentration, resulting in clinical failure despite an in vitro susceptible report. Multiple case series and clinical studies have documented cephalosporin treatment failure in ESBL-producing bacteremia with isolates reported as susceptible on initial testing. Current IDSA guidelines and international stewardship frameworks recommend carbapenems as definitive therapy for serious ESBL-producing bacteremia.
Option A: Option A is incorrect because the susceptibility result is not definitive for ESBL-producing organisms in the bacteremia context; the inoculum effect is a systematic limitation of standard disk diffusion methodology for ESBL detection, not a host-factor phenomenon, and this is the mechanistic basis for the clinical guideline recommendation to use carbapenems rather than relying on cephalosporin disk diffusion results.
Option B: Option B is incorrect because piperacillin-tazobactam for ESBL-producing bacteremia remains controversial; the MERINO trial demonstrated that piperacillin-tazobactam was inferior to meropenem for definitive therapy of ESBL-producing and AmpC-producing Enterobacterales bacteremia, with a higher 30-day mortality in the piperacillin-tazobactam arm, and it is not considered equivalent to carbapenems for serious bloodstream infections.
Option D: Option D is incorrect because withholding carbapenem therapy pending broth microdilution MIC confirmation is not appropriate stewardship practice; the clinical decision to use a carbapenem for ESBL-producing bacteremia is supported by existing susceptibility data and clinical guidelines and does not require additional MIC testing before initiation in a hemodynamically stable but bacteremic patient.
Option E: Option E is incorrect because fosfomycin and nitrofurantoin are urinary tract agents with activity confined to the bladder and are not appropriate for treating bacteremia regardless of the urinary source; neither achieves systemic tissue concentrations sufficient to eradicate a bacteremic focus, and their use for bloodstream infection would represent a serious clinical error.
2. A 52-year-old man with a tunneled hemodialysis catheter presents with fever, chills, and bacteremia. Blood cultures grow methicillin-resistant Staphylococcus aureus (MRSA). The susceptibility panel reports the isolate as resistant to oxacillin, ampicillin-sulbactam, and all cephalosporins tested, with minimum inhibitory concentrations (MICs) for these agents all above the susceptibility breakpoint. The isolate is susceptible to vancomycin (MIC 1 mg/L), daptomycin, linezolid, and ceftaroline. The resident asks why no conventional beta-lactam is effective and what the mechanistic basis is for ceftaroline's retained activity. Which of the following correctly explains both?
A) MRSA expresses PBP2a, an alternative transpeptidase encoded by mecA with greatly reduced affinity for all conventional beta-lactam antibiotics, allowing cell wall synthesis to continue when all native PBPs are inhibited; ceftaroline retains activity because it binds an allosteric sensor domain on PBP2a that induces a conformational change transiently opening the active site to covalent inhibition — a mechanism absent in all earlier beta-lactam generations
B) MRSA produces a broad-spectrum serine beta-lactamase that rapidly hydrolyzes all conventional beta-lactams including penicillins, cephalosporins, and carbapenems before they can reach any PBP target; ceftaroline retains activity because its catechol siderophore side chain enables active transport through the bacterial membrane, bypassing extracellular beta-lactamase and achieving concentrations sufficient to saturate all PBPs including native PBPs
C) MRSA resistance to beta-lactams results from overexpression of the AcrAB-TolC efflux system, which actively extrudes all beta-lactam antibiotics from the staphylococcal cell before they can bind PBPs; ceftaroline escapes efflux because its bulky N-acyl thiazolyl side chain sterically prevents recognition by the AcrB drug-binding pocket, allowing it to accumulate to inhibitory concentrations
D) MRSA resistance to beta-lactams arises through mutations in the native PBP2 transpeptidase active site that reduce affinity for all beta-lactam classes simultaneously; ceftaroline retains activity because it targets PBP1 exclusively, which remains unmutated in MRSA and whose inhibition alone is sufficient to block peptidoglycan synthesis when PBP2 is already non-functional
E) MRSA resistance to beta-lactams is mediated by vanA-type D-Ala-D-Lac substitution in the peptidoglycan precursor, which prevents beta-lactams from binding the terminal D-Ala-D-Ala substrate they require for PBP active site recognition; ceftaroline retains activity because it binds the D-Ala-D-Lac terminus with higher affinity than conventional beta-lactams due to a fluorine substituent on its thiazolyl ring
ANSWER: A
Rationale:
Option A is correct. MRSA resistance to all conventional beta-lactams is mediated by PBP2a, an alternative transpeptidase enzyme encoded by the mecA gene carried on the staphylococcal cassette chromosome mec (SCCmec). PBP2a has a conformationally closed transpeptidase active site that prevents conventional beta-lactams from forming the covalent acyl-enzyme intermediate required for inhibition; when all native PBPs (1, 2, 3, and 4) are occupied by the drug, PBP2a continues performing the transpeptidation step of peptidoglycan cross-linking, allowing cell survival. Ceftaroline (and ceftobiprole) uniquely overcome this barrier through a two-step allosteric mechanism: the drug first binds a sensor domain on PBP2a distant from the transpeptidase active site, inducing a conformational change that transiently opens the active site, and then forms the standard covalent acyl-enzyme complex with the catalytic serine — a mechanism that no earlier beta-lactam generation possesses. This is why ceftaroline is the only currently approved beta-lactam with MRSA activity on the susceptibility report.
Option B: Option B is incorrect because MRSA's primary resistance mechanism is PBP2a target bypass, not broad-spectrum beta-lactamase hydrolysis; the PC1 beta-lactamase in S. aureus has a narrow spectrum confined to penicillins and does not hydrolyze cephalosporins or carbapenems, and ceftaroline does not carry a catechol siderophore (that structure belongs to cefiderocol).
Option C: Option C is incorrect because AcrAB-TolC is an Enterobacterales RND efflux system; S. aureus is a Gram-positive organism without an outer membrane and does not harbor RND tripartite pumps, and efflux is not the mechanism of pan-beta-lactam resistance in MRSA.
Option D: Option D is incorrect because MRSA resistance arises through acquisition of an alternative PBP (PBP2a), not through mutations in the native PBP2; the native PBPs in MRSA are fully functional and still inhibited by beta-lactams — the problem is that PBP2a takes over the transpeptidation function, not that all PBPs have been mutated.
Option E: Option E is incorrect because D-Ala-D-Lac substitution is the VanA/VanB mechanism of vancomycin resistance in enterococci and VRSA; this mechanism affects glycopeptide binding to the peptidoglycan precursor, not beta-lactam binding to PBPs, and has no role in beta-lactam resistance in MRSA.
3. A 67-year-old man with multiple myeloma and a recent prolonged ICU admission is transferred to your service with Klebsiella pneumoniae bacteremia. Molecular resistance testing confirms KPC (Klebsiella pneumoniae carbapenemase) production. The isolate has the following MICs: meropenem 16 mg/L (resistant), ertapenem >8 mg/L (resistant), ceftazidime-avibactam 0.5/4 mg/L (susceptible), colistin 0.5 mg/L (susceptible). The fellow asks why ceftazidime-avibactam is effective against KPC when meropenem is not, and whether meropenem at high doses might still work. Which of the following is the most clinically sound response?
A) High-dose extended-infusion meropenem (2 g over 3 hours every 8 hours) should be attempted before using ceftazidime-avibactam, because pharmacodynamic modeling shows that maximizing the time above MIC with extended infusion reliably achieves bactericidal concentrations against KPC-producing isolates with meropenem MICs up to 32 mg/L, making ceftazidime-avibactam unnecessary in this patient
B) Colistin monotherapy is the preferred agent because colistin MIC of 0.5 mg/L indicates full susceptibility, colistin has bactericidal activity against all Gram-negative organisms regardless of beta-lactamase content, and the renal toxicity of colistin is manageable with hydration; ceftazidime-avibactam should be reserved for organisms resistant to colistin
C) Ceftazidime-avibactam and meropenem should be used in combination because avibactam inhibits KPC but simultaneously increases meropenem's outer membrane penetration by a porin-activating mechanism, making the combination synergistic through a dual mechanism that neither drug achieves independently
D) Meropenem remains the preferred agent despite the resistant MIC because the MIC breakpoint for carbapenem-resistant organisms was set conservatively by CLSI; for KPC-producing isolates with meropenem MICs between 8 and 16 mg/L, standard meropenem dosing achieves time above MIC values sufficient for clinical cure in immunocompromised patients with bacteremia
E) Ceftazidime-avibactam is the appropriate targeted therapy for this KPC-producing K. pneumoniae bacteremia; avibactam is a diazabicyclooctane inhibitor that forms a reversible covalent complex with the KPC serine active site, restoring ceftazidime's antibacterial activity; meropenem at any dose is not appropriate definitive therapy for an isolate with a meropenem MIC of 16 mg/L given documented clinical failures with carbapenem monotherapy against KPC producers
ANSWER: E
Rationale:
Option E is correct. KPC enzymes are class A serine carbapenemases that efficiently hydrolyze meropenem and all other carbapenems; an isolate with a meropenem MIC of 16 mg/L is clinically resistant, and carbapenem monotherapy for KPC-producing bacteremia with this MIC has been associated with high mortality in observational studies. Avibactam is a diazabicyclooctane (non-beta-lactam) beta-lactamase inhibitor that acylates the serine residue in the KPC active site, forming a slowly reversible covalent complex that protects ceftazidime from hydrolysis; ceftazidime itself retains the ability to bind PBPs and inhibit cell wall synthesis once protected from KPC-mediated degradation. The susceptible ceftazidime-avibactam MIC of 0.5/4 mg/L confirms that this combination is active against the isolate and is the correct targeted choice.
Option A: Option A is incorrect because extended-infusion meropenem does not reliably achieve bactericidal exposure against KPC-producing isolates with MICs of 16 mg/L; pharmacokinetic-pharmacodynamic modeling shows that achieving 40% fT>MIC against an MIC of 16 mg/L is not reliably achievable at standard or even high-dose meropenem regimens in patients with normal renal function, and clinical failure rates with meropenem monotherapy against high-MIC KPC producers are well documented.
Option B: Option B is incorrect because colistin monotherapy for serious KPC-producing bacteremia is associated with high mortality and nephrotoxicity; current infectious disease guidelines recommend colistin as a component of combination therapy rather than monotherapy for KPC-producing infections, and ceftazidime-avibactam with its established efficacy against KPC is preferred when susceptible.
Option C: Option C is incorrect because avibactam does not activate porins or increase meropenem outer membrane penetration; avibactam's sole mechanism of action is beta-lactamase inhibition through active site acylation, and there is no established porin-activating mechanism for avibactam.
Option D: Option D is incorrect because CLSI breakpoints for carbapenem-resistant organisms are not set conservatively; a meropenem MIC of 16 mg/L is genuinely resistant by any standard methodology, and pharmacodynamic modeling does not support using meropenem at standard doses against isolates with MICs at this level, particularly in immunocompromised patients where bacterial clearance is already impaired.
4. A 61-year-old man is in the medical ICU with ventilator-associated pneumonia. Initial bronchoalveolar lavage cultures grow Enterobacter cloacae susceptible to ceftriaxone, ceftazidime, and piperacillin-tazobactam but resistant to ampicillin. He is started on ceftriaxone. On hospital day 9 his clinical status worsens; repeat cultures grow Enterobacter cloacae now resistant to ceftriaxone, ceftazidime, cefepime, and piperacillin-tazobactam, but susceptible to meropenem and ertapenem. Susceptibility testing shows resistance is not inhibited by clavulanic acid. Which of the following most accurately explains the resistance pattern and guides appropriate therapy?
A) The patient has acquired a new nosocomial infection with a different Enterobacter cloacae strain carrying a plasmid-encoded extended-spectrum beta-lactamase (ESBL); the susceptibility pattern including clavulanic acid non-inhibition is consistent with a CTX-M variant ESBL that has mutated to escape clavulanic acid inhibition, and therapy should be changed to meropenem with addition of colistin for double coverage
B) Enterobacter cloacae carries an inducible chromosomal AmpC beta-lactamase; ceftriaxone therapy selected for de-repressed mutants that constitutively overproduce AmpC, conferring resistance to all cephalosporins and piperacillin-tazobactam — neither of which inhibits AmpC — while carbapenems remain active; the appropriate response is to change therapy to meropenem or ertapenem
C) The pattern is explained by progressive accumulation of outer membrane porin mutations selected by beta-lactam exposure, reducing permeability to ceftriaxone, ceftazidime, and cefepime sequentially; piperacillin-tazobactam resistance followed because tazobactam increases porin expression as an off-target effect; carbapenem activity is preserved because imipenem uses OprD-type porins not affected by these mutations
D) Fluoroquinolone cross-resistance selected by prolonged ceftriaxone exposure through SOS response activation explains the new beta-lactam resistance pattern; the shared target mechanism between fluoroquinolones and some beta-lactams at the level of PBP3 means that de-repression of the quinolone resistance pathway simultaneously confers cephalosporin resistance
E) The Enterobacter cloacae has undergone phenotypic switching to a biofilm-producing variant selected by ceftriaxone exposure; biofilm-associated organisms are resistant to all beta-lactams due to reduced penetration of the polysaccharide matrix and slow-growing phenotype that renders beta-lactam-mediated bactericidal killing ineffective, while carbapenems retain activity because of their superior biofilm penetration compared to cephalosporins
ANSWER: B
Rationale:
Option B is correct. Enterobacter cloacae is a classical member of the ESCAPPM group (Enterobacter, Serratia, Citrobacter freundii, Acinetobacter, Proteus vulgaris, Providencia, and Morganella), all of which carry chromosomally encoded inducible AmpC beta-lactamases. Under basal conditions AmpC expression is repressed and these organisms appear susceptible to extended-spectrum cephalosporins. Third-generation cephalosporins such as ceftriaxone are potent inducers of AmpC and also powerfully select pre-existing de-repressed mutants — typically organisms with loss-of-function mutations in the AmpD regulatory gene — that constitutively overproduce AmpC at high levels. De-repressed AmpC confers broad cephalosporin resistance across all generations including cefepime in many isolates, and AmpC is intrinsically resistant to inhibition by classical beta-lactamase inhibitors including clavulanic acid and tazobactam, explaining why piperacillin-tazobactam is also affected. Carbapenems are poor AmpC substrates and retain activity, making meropenem or ertapenem the appropriate treatment change. This on-therapy resistance emergence pattern is a well-recognized complication of third-generation cephalosporin use for serious Enterobacter infections and is why cephalosporins are generally avoided as monotherapy for this genus.
Option A: Option A is incorrect because ESBL enzymes are characteristically inhibited by clavulanic acid, not resistant to it; the clavulanic acid non-inhibition result is the key phenotypic clue pointing toward AmpC rather than ESBL, and de novo acquisition of a new ESBL-producing strain does not explain the orderly resistance emergence pattern on serial cultures during cephalosporin therapy.
Option C: Option C is incorrect because sequential porin mutation is not the established mechanism for the rapid pan-cephalosporin resistance pattern described; porin loss typically contributes to carbapenem resistance when combined with a beta-lactamase, and tazobactam does not upregulate porin expression.
Option D: Option D is incorrect because fluoroquinolone cross-resistance through SOS response activation does not cause beta-lactam resistance; fluoroquinolones and beta-lactams target entirely different cellular pathways (topoisomerases versus PBPs), and there is no shared resistance mechanism between them that would produce this pattern.
Option E: Option E is incorrect because while biofilm can reduce antibiotic efficacy, phenotypic switching to a biofilm variant does not explain orderly pan-cephalosporin resistance with preserved carbapenem susceptibility in a quantitative culture result; AmpC de-repression is the established mechanistic explanation for this specific clinical scenario.
5. A 44-year-old man with end-stage renal disease on peritoneal dialysis is found to have Enterococcus faecium native valve endocarditis. Blood cultures confirm vancomycin-resistant E. faecium (VRE) with vancomycin MIC greater than 256 mg/L. Molecular testing reveals vanA genotype. The susceptibility panel shows the isolate is resistant to vancomycin and ampicillin, with susceptibility reported for linezolid (MIC 1 mg/L), daptomycin (MIC 2 mg/L), and teicoplanin (MIC 0.5 mg/L). The infectious disease fellow notes that the teicoplanin susceptibility in a vanA isolate is unexpected and asks for clarification, and also asks which agent is most appropriate for treatment. Which of the following is correct?
A) Vancomycin at maximally aggressive dosing targeting AUC/MIC above 400 should be attempted first because vanA confers only moderate-level vancomycin resistance in E. faecium; high-dose continuous infusion vancomycin achieves concentrations sufficient to overcome vanA-mediated resistance in the setting of prolonged endocarditis therapy, and teicoplanin susceptibility confirms that the vanA cluster is not fully expressed
B) Teicoplanin is the drug of choice for this vanA VRE endocarditis because the reported teicoplanin susceptibility with MIC 0.5 mg/L confirms that the D-Ala-D-Lac substitution encoded by vanA has incomplete penetrance in this isolate under in vitro testing conditions; teicoplanin's superior protein binding and longer half-life compared to vancomycin make it the preferred glycopeptide for endocarditis caused by glycopeptide-modified organisms
C) Linezolid should not be used for endocarditis because it is bacteriostatic against enterococci and lacks FDA approval for endocarditis; high-dose daptomycin monotherapy is the only evidence-supported option for VRE endocarditis, with the reported daptomycin MIC of 2 mg/L confirming susceptibility at the endocarditis dosing threshold of 8-10 mg/kg/day
D) Daptomycin (high-dose, 8-10 mg/kg/day for endocarditis) or linezolid are appropriate options for this vanA VRE endocarditis; the reported teicoplanin susceptibility is an in vitro artifact — teicoplanin does not induce the vanA biosynthetic pathway in testing conditions, so the organism continues making D-Ala-D-Ala precursors that appear susceptible to teicoplanin in vitro but teicoplanin exposure in vivo will induce full vanA expression and treatment failure is expected
E) Ampicillin plus gentamicin synergy is the preferred regimen for VRE endocarditis because the high-level cell wall disruption caused by ampicillin at above-MIC concentrations overcomes vanA-mediated PBP modification through a saturation mechanism; the VRE resistance to ampicillin on the susceptibility report reflects standard breakpoints that do not account for the synergistic killing achievable with beta-lactam and aminoglycoside combination
ANSWER: D
Rationale:
Option D is correct. For vanA VRE endocarditis, daptomycin at endocarditis dosing (8-10 mg/kg/day, higher than the standard 6 mg/kg/day used for bacteremia) and linezolid are the primary treatment options supported by clinical evidence and guidelines. The teicoplanin susceptibility result for a vanA isolate requires mechanistic interpretation: vanA expression is regulated by the VanSA/VanRA two-component system, which is induced by vancomycin but also by teicoplanin. However, in standard in vitro susceptibility testing conditions, teicoplanin may not trigger sufficient vanA induction, and the organism continues producing D-Ala-D-Ala precursors that bind teicoplanin normally, generating a falsely susceptible result. When teicoplanin is used clinically for vanA VRE, induction of the vanA pathway occurs and treatment failure results — this phenomenon is well documented and is why teicoplanin is considered unreliable for vanA VRE despite in vitro susceptibility reports. The reported teicoplanin susceptibility is therefore a testing artifact, not a clinically actionable result.
Option A: Option A is incorrect because vanA confers high-level vancomycin resistance with MICs typically exceeding 64 mg/L and often above 256 mg/L, as in this patient; no dosing strategy can overcome this level of resistance, and AUC/MIC-guided dosing optimization is not effective when the MIC itself reflects near-complete loss of drug-target interaction.
Option B: Option B is incorrect because teicoplanin susceptibility in a vanA isolate is a testing artifact rather than evidence of incomplete resistance penetrance; using teicoplanin for vanA VRE endocarditis based on an in vitro susceptible result is expected to produce clinical failure through induction of the vanA pathway during therapy.
Option C: Option C is incorrect because while linezolid is bacteriostatic against enterococci, it has been used successfully as salvage therapy for VRE endocarditis and is not excluded from consideration on the basis of its bacteriostatic activity; the statement that high-dose daptomycin is the "only evidence-supported option" overstates the exclusion of linezolid.
Option E: Option E is incorrect because the isolate is reported resistant to ampicillin — enterococcal ampicillin resistance is mediated by PBP5 overexpression or mutation and is a genuine clinical resistance that cannot be overcome by combining with an aminoglycoside; the saturation mechanism described does not exist, and ampicillin-based therapy for an ampicillin-resistant isolate is not appropriate.
6. A 55-year-old woman with leukemia returns from medical tourism surgery in India and develops a Klebsiella pneumoniae bloodstream infection. Molecular testing confirms NDM (New Delhi metallo-beta-lactamase) production. The isolate is resistant to all carbapenems, ceftazidime-avibactam, and ceftolozane-tazobactam. It is susceptible to aztreonam-avibactam (MIC 0.5/4 mg/L) and colistin. The fellow asks why ceftazidime-avibactam fails against NDM when it is effective against KPC, and why aztreonam-avibactam retains activity. Which of the following is the most accurate explanation?
A) Ceftazidime-avibactam fails against NDM because NDM produces a conformational change in the outer membrane that prevents avibactam from reaching the periplasm where NDM is located; aztreonam-avibactam overcomes this because aztreonam's monocyclic structure enables diffusion through alternative outer membrane channels that NDM-producing organisms upregulate as a compensatory porin response
B) Ceftazidime-avibactam fails against NDM because NDM efficiently hydrolyzes ceftazidime before avibactam can protect it; aztreonam-avibactam retains activity because avibactam chelates the zinc ions in the NDM active site, inactivating the enzyme and allowing aztreonam to reach PBPs intact
C) Ceftazidime-avibactam fails against NDM because avibactam inhibits only serine beta-lactamases (class A and D) through active site acylation — NDM is a class B metallo-beta-lactamase that uses zinc ions rather than a serine residue and is therefore not inhibited by avibactam; aztreonam, as a monobactam, is not hydrolyzed by metallo-beta-lactamases, and avibactam in the combination inhibits co-produced serine beta-lactamases that would otherwise hydrolyze aztreonam
D) Ceftazidime-avibactam fails against NDM because NDM producers universally co-produce KPC, and KPC hydrolysis of ceftazidime overwhelms avibactam's inhibitory capacity at standard dosing; aztreonam-avibactam retains activity because aztreonam is a KPC substrate with a 100-fold lower kcat than ceftazidime, making avibactam sufficient to protect it even in the presence of both NDM and KPC
E) Ceftazidime-avibactam fails against NDM because ceftazidime cannot bind PBP2 in NDM-producing organisms due to a secondary PBP modification that co-segregates with NDM gene acquisition on the same plasmid; aztreonam-avibactam retains activity because aztreonam targets PBP3 exclusively, which remains unmodified in NDM-producing organisms
ANSWER: C
Rationale:
Option C is correct. The mechanistic explanation requires understanding both avibactam's class specificity and aztreonam's unique structural relationship to metallo-beta-lactamases. Avibactam is a diazabicyclooctane inhibitor that works by forming a covalent acyl-enzyme complex with the serine residue in the active site of class A (including KPC, CTX-M, TEM) and certain class D (OXA-48) serine beta-lactamases; it has no activity against class B metallo-beta-lactamases because these enzymes use zinc ions rather than serine for catalysis, and avibactam has no zinc chelating activity. NDM is a class B MBL, so avibactam cannot protect ceftazidime from NDM-mediated hydrolysis. Aztreonam, as a monobactam with a monocyclic beta-lactam ring, is structurally resistant to hydrolysis by metallo-beta-lactamases including NDM — MBLs evolved to hydrolyze bicyclic beta-lactams (penicillins, cephalosporins, carbapenems) and do not efficiently hydrolyze the monocyclic aztreonam ring. However, NDM-producing organisms frequently co-produce serine beta-lactamases (ESBLs, AmpC, or KPC) encoded on the same or companion plasmids, and these serine enzymes would destroy aztreonam without avibactam protection. The combination therefore works because aztreonam escapes NDM and avibactam neutralizes co-produced serine enzymes.
Option A: Option A is incorrect because avibactam does not chelate zinc and does not overcome NDM through alternative porin pathways; the mechanism is enzyme class specificity, not permeability.
Option B: Option B is incorrect because avibactam does not chelate zinc or inactivate metallo-beta-lactamases; this is a fundamental mechanistic error — avibactam targets serine residues exclusively, and NDM has no active site serine.
Option D: Option D is incorrect because NDM producers do not universally co-produce KPC; NDM and KPC are distinct carbapenemase families that can co-occur but do not co-segregate obligatorily, and the explanation for ceftazidime-avibactam failure against NDM is avibactam's inability to inhibit the zinc-dependent NDM enzyme, not competitive KPC hydrolysis.
Option E: Option E is incorrect because aztreonam targets PBP3 (also known as FtsI) in addition to other PBPs, and there is no established PBP modification that co-segregates with NDM acquisition; PBP modification is the MRSA mechanism, not an NDM-associated phenomenon in Gram-negative bacteria.
7. A 70-year-old woman with a biliary stent is admitted with cholangitis. Blood cultures grow Serratia marcescens. The susceptibility report shows the isolate is susceptible to piperacillin-tazobactam (MIC 8/4 mg/L, within the susceptible range), meropenem, and ciprofloxacin; it is resistant to ampicillin and ampicillin-sulbactam. The resident proposes treating with piperacillin-tazobactam. Before approving this plan for a serious bloodstream infection, the attending asks whether the piperacillin-tazobactam susceptibility result can be relied upon for this organism. Which of the following is the most accurate statement regarding this clinical decision?
A) Serratia marcescens belongs to the ESCAPPM group and carries an inducible chromosomal AmpC beta-lactamase that is intrinsically resistant to inhibition by tazobactam; the in vitro piperacillin-tazobactam susceptibility may not predict clinical outcome in bacteremia, and for serious Serratia infections a carbapenem is the more reliable choice, particularly given the risk of AmpC de-repression during therapy
B) The piperacillin-tazobactam susceptibility result is fully reliable for Serratia because tazobactam has a broader inhibitory spectrum than clavulanic acid and sulbactam, covering all Ambler class A, C, and D enzymes; the susceptibility result at MIC 8/4 mg/L confirms that tazobactam is fully suppressing AmpC activity and that clinical failure is not expected
C) The carbapenem susceptibility result rather than the piperacillin-tazobactam result is the key finding here; the carbapenem susceptibility confirms the absence of any carbapenemase, meaning that the isolate cannot acquire a carbapenemase on an emerging plasmid during therapy, and this makes piperacillin-tazobactam safe to use because the only remaining resistance risk — plasmid-mediated carbapenemase acquisition — is excluded
D) The piperacillin-tazobactam MIC of 8/4 mg/L falls exactly at the pharmacokinetic-pharmacodynamic (PK/PD) target boundary; extended-infusion piperacillin-tazobactam (4.5 g over 4 hours every 8 hours) will reliably achieve time above MIC values sufficient to overcome AmpC-mediated hydrolysis in Serratia bacteremia and is considered equivalent to carbapenem therapy in this specific MIC range for cholangitis
E) The ampicillin-sulbactam resistance on the susceptibility report indicates that Serratia has acquired a plasmid-encoded metalloprotease that degrades all available beta-lactamase inhibitors including tazobactam; the piperacillin-tazobactam susceptibility result is therefore a laboratory artifact caused by insufficient metalloprotease expression at the testing inoculum, and carbapenem therapy is required
ANSWER: A
Rationale:
Option A is correct. Serratia marcescens is a member of the ESCAPPM group, all of which carry chromosomally encoded inducible AmpC beta-lactamases. AmpC is a class C serine enzyme that is intrinsically resistant to inhibition by classical beta-lactamase inhibitors — clavulanic acid, sulbactam, and tazobactam — because the structural geometry of the AmpC active site prevents these inhibitors from forming stable inhibitory complexes. The in vitro piperacillin-tazobactam susceptibility result reflects testing conditions where AmpC expression may be at basal (repressed) levels; during clinical therapy, several factors — including the drug itself and the higher bacterial burdens in infection — can favor de-repression of AmpC, resulting in in vivo resistance despite the susceptible in vitro MIC. This inoculum effect and de-repression risk are well established for ESCAPPM organisms, and most infectious disease guidelines recommend carbapenems rather than piperacillin-tazobactam for serious Serratia bacteremia, particularly when there is no contraindication to carbapenem use.
Option B: Option B is incorrect because tazobactam does not inhibit class C AmpC enzymes; it inhibits class A serine beta-lactamases (TEM, SHV, CTX-M-type ESBLs), and the assertion that tazobactam covers all Ambler class A, C, and D enzymes is pharmacologically incorrect.
Option C: Option C is incorrect because the absence of carbapenemase is not the relevant clinical concern in this case; the concern is AmpC-mediated piperacillin-tazobactam failure during therapy, which occurs through de-repression of a pre-existing chromosomal enzyme rather than acquisition of a new plasmid-encoded carbapenemase.
Option D: Option D is incorrect because extended-infusion piperacillin-tazobactam is not considered equivalent to carbapenem therapy for serious ESCAPPM bacteremia; the MERINO trial and observational data confirm inferior outcomes with piperacillin-tazobactam compared to carbapenems for serious Enterobacterales bacteremia where AmpC activity is relevant, and extended infusion does not overcome intrinsic tazobactam non-inhibition of AmpC.
Option E: Option E is incorrect because ampicillin-sulbactam resistance in Serratia reflects intrinsic resistance due to AmpC expression and outer membrane permeability — not acquisition of a metalloprotease; Serratia has natural intrinsic resistance to ampicillin regardless of AmpC de-repression, and the mechanism described does not correspond to any established resistance mechanism in Enterobacterales.
8. A 28-year-old man presents with a large abscess on his thigh. The abscess is incised and drained, and wound cultures grow community-acquired MRSA (CA-MRSA). The susceptibility report shows the isolate is resistant to oxacillin and erythromycin, and susceptible to clindamycin by standard disk diffusion. However, the laboratory has added a notation: "Inducible clindamycin resistance detected — D-zone test positive." The resident asks what this means and whether clindamycin can still be used. Which of the following correctly explains the D-zone result and its clinical implications?
A) The D-zone positive result confirms that this isolate carries the msrA gene encoding an ABC-type efflux pump that exports both erythromycin and clindamycin; the erythromycin disk placed adjacent to the clindamycin disk during D-zone testing induces msrA efflux pump expression, which then reduces clindamycin accumulation and produces the characteristic flattening of the clindamycin inhibition zone
B) The D-zone positive result indicates that the isolate carries the vanB gene cluster, which can be induced by erythromycin in some MRSA strains to produce cross-resistance to macrolide-lincosamide-streptogramin B antibiotics; clindamycin can be used safely because vanB-mediated resistance affects only the 50S ribosomal subunit in enterococci, not in staphylococci
C) The D-zone positive result indicates that the isolate carries a constitutively expressed erm gene; because erm is already fully expressed at baseline, the D-zone test detects residual erythromycin diffusion that artificially reduces the clindamycin zone diameter; the isolate is truly susceptible to clindamycin and the antibiotic can be prescribed with confidence
D) The D-zone positive result means that the isolate carries a chromosomal mutation in the L4 ribosomal protein that is induced by erythromycin exposure and confers post-induction cross-resistance to clindamycin; because this mutation affects protein structure rather than rRNA methylation, clindamycin can be used at high doses to overcome the reduced ribosomal binding affinity
E) The D-zone positive result indicates that the isolate carries an inducible erm gene whose expression is suppressed at baseline, making the organism appear clindamycin-susceptible on routine testing; erythromycin (or macrolide exposure in vivo) can induce erm expression, producing the full macrolide-lincosamide-streptogramin B (MLSB) resistance phenotype and clinical clindamycin failure; whether clindamycin is used depends on clinical judgment, but the risk of induction failure is real
ANSWER: E
Rationale:
Option E is correct. The erm gene family encodes methyltransferases that methylate adenine A2058 in 23S rRNA, conferring resistance to macrolides, lincosamides (clindamycin), and streptogramin B simultaneously — the MLSB phenotype. erm expression can be constitutive (always on, detectable by standard susceptibility testing) or inducible (suppressed at baseline by translational attenuation involving a regulatory leader peptide in the mRNA). Inducible erm isolates appear clindamycin-susceptible on routine testing because erm is not expressed in the absence of an inducer. The D-zone test places an erythromycin disk adjacent to a clindamycin disk on the susceptibility plate: if erm is inducible, erythromycin (a macrolide and potent erm inducer) diffusing from its disk induces erm expression in the zone between the two disks, reducing clindamycin efficacy in that region and flattening the normally circular clindamycin inhibition zone into a D-shape. A D-zone positive result means inducible MLSB resistance is present; clindamycin use risks inducing erm expression during therapy and clinical failure. Most guidelines advise against clindamycin for serious MRSA infections with D-zone positive results, though it may be considered for mild uncomplicated infections with careful monitoring.
Option A: Option A is incorrect because the D-zone test detects erm-mediated inducible MLSB resistance, not msrA efflux-mediated resistance; msrA confers resistance to macrolides and streptogramins B but not to lincosamides, so clindamycin susceptibility would not be affected by msrA induction — the characteristic D-zone result reflects erm-based ribosomal methylation, not efflux.
Option B: Option B is incorrect because vanB is a glycopeptide resistance determinant in enterococci that reprograms peptidoglycan precursor biosynthesis; it has no relation to macrolide or clindamycin resistance in staphylococci, and there is no mechanism by which vanB would produce the D-zone result.
Option C: Option C is incorrect because constitutively expressed erm produces overt clindamycin resistance detectable on routine susceptibility testing — the organism would not appear clindamycin-susceptible; the D-zone test is specifically designed to detect the inducible variant, and a D-zone positive result by definition identifies an inducible (not constitutive) pattern.
Option D: Option D is incorrect because L4 ribosomal protein mutations are a minor mechanism of macrolide resistance not associated with the D-zone phenomenon; erm-mediated rRNA methylation is the dominant mechanism producing the D-zone result, and high-dose clindamycin does not reliably overcome MLSB resistance once erm is induced.
9. A 58-year-old man with a healthcare-associated Pseudomonas aeruginosa urinary tract infection is being treated with ciprofloxacin. The clinical pharmacist reviews the regimen and notes that ciprofloxacin is a concentration-dependent antibiotic and asks the team to optimize dosing with resistance prevention in mind. The pharmacist explains that for fluoroquinolones, a specific pharmacokinetic-pharmacodynamic (PK/PD) parameter correlates best with both clinical efficacy and prevention of resistance emergence. Which of the following correctly identifies this parameter and explains why it governs resistance prevention?
A) The time above MIC (fT>MIC) expressed as the percentage of the dosing interval during which free drug concentrations exceed the MIC is the primary PK/PD driver for fluoroquinolone efficacy and resistance prevention; once-daily dosing is therefore suboptimal because it allows drug concentrations to fall below the MIC for extended periods, during which bacterial regrowth occurs and resistant mutants are selectively amplified
B) The AUC/MIC ratio (area under the concentration-time curve divided by the minimum inhibitory concentration) is the primary PK/PD parameter governing fluoroquinolone efficacy and resistance prevention; higher AUC/MIC ratios drive more complete bacterial killing and maintain drug concentrations above the mutant prevention concentration (MPC) for a greater proportion of the dosing interval, reducing the time drug levels dwell in the mutant selection window where resistant mutants are amplified
C) The peak concentration to MIC ratio (Cmax/MIC) is the dominant PK/PD parameter for fluoroquinolone resistance prevention; achieving a Cmax/MIC above 10 eliminates the mutant selection window by a single-hit bactericidal mechanism that kills all organisms including pre-existing resistant mutants before they can replicate, making dose-fractionation strategies irrelevant for organisms with MIC values below the peak serum concentration
D) Fluoroquinolone resistance prevention is governed primarily by the minimum bactericidal concentration (MBC) to MIC ratio for Pseudomonas aeruginosa; selecting a fluoroquinolone with MBC/MIC ratio below 4 ensures bactericidal rather than bacteriostatic activity, and bactericidal fluoroquinolones reliably prevent resistance emergence because non-replicating dead organisms cannot acquire stepwise QRDR mutations during therapy
E) The protein-binding-adjusted trough concentration (Ctrough/MIC) is the most important PK/PD parameter for fluoroquinolone resistance prevention; maintaining free trough concentrations above 0.5× MIC throughout the dosing interval ensures continuous suppression of resistant subpopulations, and once-daily dosing with ciprofloxacin achieves this target reliably against Pseudomonas aeruginosa with MIC values up to 2 mg/L
ANSWER: B
Rationale:
Option B is correct. Fluoroquinolones are concentration-dependent antibiotics, and the pharmacokinetic-pharmacodynamic parameter most strongly correlated with both clinical cure and resistance prevention is the AUC24/MIC ratio — the ratio of the total 24-hour area under the concentration-time curve to the MIC of the target organism. This relationship reflects that fluoroquinolone killing is proportional to total drug exposure (concentration × time) rather than simply to time above MIC. For resistance prevention specifically, the AUC/MIC ratio governs how long and how far drug concentrations exceed the mutant prevention concentration (MPC) — the threshold above which even single-step resistant mutants cannot grow. When AUC/MIC is high, drug concentrations remain above the MPC for a greater proportion of the dosing interval, narrowing the mutant selection window (the concentration range between MIC and MPC where resistant mutants are selectively amplified). Clinical data from respiratory tract infections and urinary tract infections support an AUC24/MIC target of approximately 125 or greater for efficacy against susceptible pathogens, with higher targets for resistance prevention against organisms like P. aeruginosa.
Option A: Option A is incorrect because time above MIC is the primary PK/PD driver for beta-lactam and vancomycin antibiotics, not fluoroquinolones; fluoroquinolones demonstrate concentration-dependent killing and their efficacy is better predicted by AUC/MIC or Cmax/MIC ratios than by fT>MIC.
Option C: Option C is incorrect because while Cmax/MIC does contribute to fluoroquinolone killing (particularly for initial inoculum reduction), it is not the dominant resistance prevention parameter; the AUC/MIC ratio is more strongly correlated with resistance prevention because it integrates total drug exposure across the dosing interval, not just the peak; furthermore, a high Cmax/MIC does not guarantee elimination of all resistant mutants in a single hit.
Option D: Option D is incorrect because MBC/MIC ratio is not an established PK/PD parameter for fluoroquinolone dosing optimization or resistance prevention; the relevant parameters are AUC/MIC and Cmax/MIC, and the description of a "single bactericidal hit" that eliminates all organisms without replication opportunity is not how fluoroquinolone resistance prevention works in practice.
Option E: Option E is incorrect because trough concentration to MIC ratio is a PK/PD parameter used primarily for vancomycin monitoring in some older frameworks; for fluoroquinolones, which are concentration-dependent, the trough is not the primary efficacy or resistance-prevention driver, and once-daily ciprofloxacin does not achieve reliable trough-based suppression of P. aeruginosa at MICs near the breakpoint.
10. An infectious disease consultant is called to advise on a 63-year-old man with a complicated urinary tract infection. Cultures grow Klebsiella pneumoniae that is resistant to all carbapenems (confirmed KPC-producer) and also resistant to colistin. Molecular testing reveals both a KPC-encoding plasmid and the mcr-1 gene. The family asks why the organism is resistant to so many antibiotics and what treatment options remain. The consultant explains the significance of the mcr-1 finding in an already carbapenem-resistant organism. Which of the following best characterizes this situation and the clinical implications of mcr-1 acquisition by a carbapenem-resistant organism?
A) The mcr-1 finding is clinically incidental in this patient because colistin is never used as monotherapy and is always combined with a carbapenem for KPC infections; since the organism is already carbapenem-resistant, the colistin-carbapenem combination was never a viable option regardless of mcr-1 status, and the treatment approach is unchanged by the mcr-1 result
B) The mcr-1 gene encodes a lipid A kinase that eliminates all negative charges from the outer membrane, making the organism impermeable to all antibiotics regardless of mechanism; the finding of mcr-1 in a carbapenem-resistant organism therefore indicates absolute pan-resistance and that further antimicrobial therapy is futile
C) The mcr-1 gene confers resistance to colistin through a chromosomal mutation mechanism that cannot be transmitted to other organisms; while concerning for this patient, the finding does not represent a public health risk because mcr-1-mediated colistin resistance is not horizontally transferable and cannot spread to other Klebsiella strains in the hospital environment
D) The combination of KPC-mediated carbapenem resistance and mcr-1-mediated colistin resistance creates a critically dangerous phenotype because colistin has historically served as a last-resort agent for carbapenem-resistant Gram-negative infections; mcr-1 is carried on conjugative plasmids and can transfer to other already carbapenem-resistant organisms, creating pan-resistant strains; remaining options may include ceftazidime-avibactam (if KPC susceptibility confirmed), fosfomycin, or novel combinations — highlighting why mcr-1 spread is an urgent global health concern
E) The mcr-1 gene is effectively suppressed in KPC-producing organisms because KPC plasmid maintenance creates a metabolic burden that down-regulates all co-resident plasmid gene expression including mcr-1; colistin MIC testing in KPC-producing organisms is therefore unreliable and the reported colistin resistance should be confirmed by a reference laboratory before treating as genuine
ANSWER: D
Rationale:
Option D is correct. Colistin (polymyxin E) has historically been one of the last-resort agents for carbapenem-resistant Gram-negative infections, used when all other options have failed — despite its significant nephrotoxicity. The emergence of mcr-1-mediated colistin resistance in organisms that are already carbapenem-resistant produces a clinical scenario of extreme limited options: two of the final-resort drug classes are simultaneously inactivated. What makes mcr-1 a specific global public health concern — beyond its occurrence in any individual patient — is that it is carried on conjugative plasmids and can transfer horizontally between organisms by conjugation, meaning it can spread from a colistin-susceptible KPC-producer to another already-resistant strain, rapidly generating pan-resistant lineages without requiring new mutation events. For this patient, treatment options require consultation with infectious disease specialists and may include ceftazidime-avibactam (if the KPC MIC confirms susceptibility, which requires checking), fosfomycin (if susceptible, particularly for urinary source), or investigational combinations.
Option A: Option A is incorrect because colistin's clinical value in KPC infections, while limited as monotherapy, extends to combination regimens that have been used for resistant Gram-negative bacteremia; mcr-1 eliminates this option and significantly narrows the therapeutic landscape, making the finding clinically important rather than incidental.
Option B: Option B is incorrect because mcr-1 encodes a phosphoethanolamine transferase that modifies lipid A charge, not a kinase that eliminates all outer membrane charges; the mechanism confers colistin resistance specifically but does not create impermeability to all antibiotics, and describing the organism as "absolutely pan-resistant" overstates what mcr-1 alone contributes.
Option C: Option C is incorrect because mcr-1 is explicitly a plasmid-mediated (horizontally transferable) resistance mechanism — this is the defining concern that elevated it to international attention when first described in 2015; characterizing it as a non-transferable chromosomal mutation is a fundamental factual error.
Option E: Option E is incorrect because there is no established mechanism by which KPC plasmid maintenance suppresses mcr-1 expression; both resistance determinants can be stably co-expressed from the same or different plasmids, and the colistin resistance result is clinically genuine and should not be dismissed as a laboratory artifact.
11. A 71-year-old man with diabetes and a chronic foot ulcer has been receiving vancomycin for MRSA osteomyelitis for six weeks. Repeat wound culture grows Staphylococcus aureus with a vancomycin MIC of 4 mg/L (intermediate range, categorized as vancomycin-intermediate S. aureus, VISA). The infectious disease team notes that the MIC has crept up from 1 mg/L at the start of therapy. Molecular testing finds no vanA or vanB genes. A medical student asks how this organism has developed reduced vancomycin susceptibility without the resistance genes seen in VRE. Which of the following correctly explains VISA and distinguishes it from VRSA?
A) VISA results from acquisition of a truncated vanB gene cluster that confers D-Ala-D-Lac substitution at approximately 30% penetrance, producing intermediate-level vancomycin resistance rather than the high-level resistance seen with fully expressed vanB; the absence of full vanB expression explains the MIC of 4 mg/L rather than the >256 mg/L seen in VRE
B) VISA results from chromosomal mutations in the vanSA/vanRA sensor-kinase system that cause constitutive low-level expression of the D-Ala-D-Lac biosynthetic pathway; unlike vanA-mediated VRE where high-level expression is inducible, the constitutive low-level D-Ala-D-Lac production in VISA produces only intermediate resistance; VRSA arises when additional mutations fully activate the pathway
C) VISA arises through a progressive accumulation of chromosomal mutations — not horizontal gene transfer — that thicken the staphylococcal cell wall and create a "vancomycin trap," sequestering glycopeptide molecules in outer peptidoglycan layers before they reach the membrane-associated synthesis sites; VRSA is a distinct phenomenon arising from conjugative transfer of vanA from VRE and represents true glycopeptide target bypass rather than drug sequestration
D) VISA results from upregulation of the walKR (VraSR) two-component regulatory system that increases PBP2 expression, which competes with vancomycin for D-Ala-D-Ala termini and reduces effective vancomycin concentration at the membrane; VRSA by contrast occurs when vancomycin MIC exceeds 64 mg/L through accumulation of five or more walKR pathway mutations, producing a quantitative continuum from VISA to VRSA through the same mechanism
E) VISA and VRSA share the same fundamental mechanism — cell wall precursor modification — but differ only in the degree of modification; VISA produces a partially modified precursor with 50% D-Ala-D-Lac and 50% D-Ala-D-Ala termini, generating intermediate vancomycin binding; VRSA produces 100% D-Ala-D-Lac through complete vanA gene cluster expression, generating full vancomycin resistance
ANSWER: C
Rationale:
Option C is correct. Vancomycin-intermediate S. aureus (VISA) and VRSA are mechanistically distinct entities that must not be conflated. VISA arises through the progressive accumulation of chromosomal point mutations (not horizontal gene transfer) that alter cell wall metabolism: mutant regulatory pathways (including walKR/VraSR and others) upregulate cell wall synthesis, producing a thickened peptidoglycan with increased D-Ala-D-Ala content in the outer layers. Vancomycin molecules bind to these abundant D-Ala-D-Ala termini in the outer cell wall and are trapped there, unable to reach the membrane-associated transglycosylase and transpeptidase sites where active cell wall synthesis is occurring — hence the term "vancomycin trap." This is a physical sequestration mechanism that reduces effective vancomycin concentrations at the target without eliminating the D-Ala-D-Ala terminus itself. Because VISA arises through mutation and not horizontal gene transfer, there are no van genes present, as confirmed in this patient. VRSA, by contrast, arises through conjugative transfer of the vanA gene cluster (on Tn1546) from VRE to MRSA and represents genuine target bypass through D-Ala-D-Lac precursor substitution — an entirely different biochemical mechanism that produces much higher MICs (typically >64 mg/L or >256 mg/L).
Option A: Option A is incorrect because VISA does not involve any truncated vanB gene; the absence of vanA or vanB genes is definitive, and VISA is not caused by any van gene cluster in any form.
Option B: Option B is incorrect for the same reason — no van gene cluster (not even a mutated vanSA/vanRA) is involved in VISA; the mechanism is chromosomal regulatory mutation causing cell wall thickening, and VRSA does not arise from further mutation of a VISA pathway.
Option D: Option D is incorrect because while walKR regulatory changes contribute to VISA, the mechanism is cell wall thickening and vancomycin trapping rather than PBP2 competition with vancomycin for D-Ala-D-Ala; VRSA does not arise through accumulation of walKR mutations and is not a quantitative continuum from VISA — it is a distinct molecular event (vanA acquisition by conjugation).
Option E: Option E is incorrect because VISA does not produce a partially modified D-Ala-D-Lac precursor; the D-Ala-D-Ala terminus remains intact in VISA, which is why vancomycin still binds — the resistance is due to physical trapping in the outer cell wall, not biochemical modification of the drug target.
12. A 66-year-old man with a prosthetic aortic valve develops Pseudomonas aeruginosa bacteremia. The isolate carries the aac(6')-Ib gene encoding an aminoglycoside acetyltransferase. The susceptibility panel reports the isolate as resistant to tobramycin and amikacin but susceptible to gentamicin, with a gentamicin MIC of 1 mg/L. The fellow is surprised that the isolate is susceptible to gentamicin but resistant to tobramycin and amikacin, and asks why this differential susceptibility exists. Which of the following correctly explains the pattern and guides aminoglycoside selection?
A) The aac(6')-Ib acetyltransferase specifically targets the 6'-amino group present on tobramycin and amikacin, adding an acetyl group that prevents ribosomal binding; gentamicin lacks the 6'-amino group and is therefore not a substrate for this enzyme, retaining susceptibility — the differential susceptibility is clinically actionable and gentamicin should be selected for aminoglycoside combination therapy
B) The aac(6')-Ib enzyme acetylates the 2''-hydroxyl group of gentamicin, producing a modified compound with paradoxically increased ribosomal affinity; the apparent gentamicin susceptibility reflects this enhanced binding rather than enzyme escape, and gentamicin will fail clinically because the acetylated compound, while ribosome-binding, does not produce bactericidal activity
C) The differential susceptibility reflects inoculum effect rather than enzyme substrate specificity; tobramycin and amikacin are tested at higher inocula by convention in P. aeruginosa susceptibility panels, and the gentamicin susceptibility result would shift to resistant if retested at equal inoculum; no aminoglycoside should be chosen based on this susceptibility panel result
D) The aac(6')-Ib enzyme modifies all aminoglycosides equally by adenylylating (nucleotidylating) the 4'-hydroxyl group shared by the entire 2-deoxystreptamine family; the reported differential susceptibility is a false positive caused by gentamicin's higher intrinsic potency against P. aeruginosa masking enzyme activity — gentamicin susceptibility should not be interpreted as enzyme escape
E) The differential susceptibility pattern indicates that the isolate carries two distinct resistance mechanisms: aac(6')-Ib for tobramycin resistance and an outer membrane porin mutation for amikacin resistance; gentamicin susceptibility confirms absence of a third distinct mechanism, but combination therapy should be avoided because gentamicin will select for the same porin mutation that already confers amikacin resistance
ANSWER: A
Rationale:
Option A is correct. The aac(6')-Ib gene encodes an aminoglycoside acetyltransferase that catalyzes acetylation of the 6'-amino group of aminoglycosides possessing this chemical substituent. Tobramycin and amikacin both carry a 6'-amino group in their chemical structure, making them substrates for aac(6')-Ib-mediated acetylation; acetylation at this position abolishes the ability of these aminoglycosides to bind the 16S rRNA of the 30S ribosomal subunit. Gentamicin, by contrast, is a mixture of closely related C1, C1a, and C2 components whose relevant structural position is substituted differently — gentamicin lacks the 6'-amino group and is therefore not acetylated by aac(6')-Ib, allowing it to retain full ribosomal binding and antibacterial activity. This enzyme-substrate specificity is clinically actionable: when aac(6')-Ib is confirmed and the susceptibility panel reports gentamicin susceptible with tobramycin and amikacin resistant, gentamicin is the correct aminoglycoside selection for combination therapy (e.g., with a beta-lactam for P. aeruginosa bacteremia). This case illustrates why testing the specific intended aminoglycoside rather than assuming class resistance is essential.
Option B: Option B is incorrect because aac(6')-Ib is an acetyltransferase that modifies the 6'-amino group of its substrates (tobramycin and amikacin), not the 2''-hydroxyl; gentamicin is not modified by this enzyme at all — the gentamicin susceptibility reflects genuine enzyme escape, and clinical activity should be expected.
Option C: Option C is incorrect because the differential susceptibility between tobramycin/amikacin and gentamicin in the setting of confirmed aac(6')-Ib is a well-established, enzyme-substrate-specificity-based phenomenon, not an inoculum artifact; standardized susceptibility testing uses equal inocula for all antibiotics within a panel, and the result is clinically meaningful.
Option D: Option D is incorrect because aac(6')-Ib is an acetyltransferase, not an adenylyltransferase (nucleotidyltransferase); the ANT (aminoglycoside nucleotidyltransferase) enzymes modify different positions and different substrates — conflating the enzyme classes represents a category error.
Option E: Option E is incorrect because the susceptibility pattern described (tobramycin resistant, amikacin resistant, gentamicin susceptible) is precisely what aac(6')-Ib alone predicts based on substrate specificity; invoking a separate porin mutation to explain amikacin resistance is mechanistically unnecessary and not supported by the pattern.
13. A 74-year-old man with bronchiectasis develops a Pseudomonas aeruginosa pneumonia exacerbation requiring hospitalization. The susceptibility panel reports the isolate as resistant to imipenem (MIC 16 mg/L) but susceptible to meropenem (MIC 1 mg/L). The isolate also tests susceptible to ceftazidime, ciprofloxacin, and tobramycin. Modified carbapenem inactivation method testing is negative for carbapenemase production. The team asks which carbapenem, if any, is appropriate and what accounts for the selective imipenem resistance. Which of the following is the correct clinical interpretation and management approach?
A) The discordant carbapenem susceptibility is a laboratory artifact caused by instability of imipenem at room temperature during transit to the microbiology lab; imipenem and meropenem have identical mechanisms of action and PBP binding profiles, so they cannot differ in susceptibility against a non-carbapenemase-producing organism — both should be reported as equally susceptible or both retested with fresh drug
B) The selective imipenem resistance with preserved meropenem susceptibility indicates that the organism carries a KPC carbapenemase with narrow substrate specificity for imipenem; meropenem is not hydrolyzed by this variant KPC because of its 1-beta-methyl group; the negative mCIM result reflects a low-expression KPC that does not produce enough enzyme to turn the test positive, and meropenem should be used with caution anticipating possible clinical failure
C) The organism is resistant to imipenem because imipenem induces the MexAB-OprM efflux system through a cell wall stress pathway, and imipenem is a better MexAB-OprM substrate than meropenem; because meropenem does not induce this efflux system, it retains susceptibility; treating with meropenem is appropriate, but adding a second anti-Pseudomonal agent is essential to prevent meropenem from inducing MexAB-OprM during therapy
D) The discordant result indicates acquisition of a narrow-spectrum OXA-type carbapenemase (OXA-48 subgroup) that preferentially hydrolyzes imipenem because of the structural complementarity between imipenem's hydroxyethyl side chain and the OXA-48 active site; the negative mCIM test is a known false negative for OXA-48 type enzymes; meropenem should be used but aztreonam-avibactam should be added empirically given the OXA concern
E) The selective imipenem resistance with preserved meropenem susceptibility is explained by loss of OprD, the outer membrane porin that serves as the primary entry channel for imipenem into the P. aeruginosa periplasm; because meropenem is less dependent on OprD for periplasmic entry and is a poorer substrate for constitutive MexAB-OprM efflux, it retains activity; meropenem is the appropriate carbapenem choice, and the negative carbapenemase test confirms that resistance is mechanism-based rather than enzyme-mediated
ANSWER: E
Rationale:
Option E is correct. The imipenem-resistant, meropenem-susceptible phenotype in P. aeruginosa without a carbapenemase is a well-characterized clinical phenomenon explained by loss of OprD. OprD is a specific outer membrane channel protein (porin) in P. aeruginosa that serves as the primary entry pathway for imipenem into the periplasm; imipenem has high structural complementarity for OprD and depends on it more heavily than meropenem for outer membrane penetration. Loss of OprD through chromosomal mutation — a readily selectable event during carbapenem therapy — selectively reduces imipenem entry without abolishing meropenem activity. Meropenem retains activity because it is less exclusively dependent on OprD for periplasmic access and because it is a poorer substrate for the constitutively expressed MexAB-OprM efflux system than imipenem; meropenem can diffuse through residual permeability pathways at concentrations sufficient to maintain activity against susceptible isolates. The negative carbapenemase test confirms the mechanism is structural (porin loss) rather than enzymatic. Meropenem is the correct carbapenem choice for this patient based on the susceptibility result.
Option A: Option A is incorrect because imipenem and meropenem do differ meaningfully in susceptibility in clinical P. aeruginosa isolates; imipenem stability at room temperature does not account for a 16-fold MIC difference (16 vs 1 mg/L), and the OprD-mediated mechanism is a well-validated explanation for this specific pattern.
Option B: Option B is incorrect because KPC carbapenemases do not have substrate selectivity for imipenem over meropenem — KPC efficiently hydrolyzes both; selective imipenem resistance with meropenem susceptibility and a negative carbapenemase test is inconsistent with any known carbapenemase mechanism.
Option C: Option C is incorrect because MexAB-OprM is not selectively induced by imipenem in a clinically meaningful way that explains this MIC difference; the dominant explanation for imipenem-selective resistance in non-carbapenemase P. aeruginosa is OprD loss, not differential efflux induction.
Option D: Option D is incorrect because OXA-48 type carbapenemases do not preferentially hydrolyze imipenem over meropenem, and OXA-48 does not cause the clean imipenem-resistant, meropenem-susceptible pattern with a negative mCIM test; the mCIM is not known to be specifically false-negative for OXA-48.
14. A 59-year-old woman with liver failure is in the ICU with Acinetobacter baumannii ventilator-associated pneumonia. The isolate is resistant to all carbapenems (OXA-23 carbapenemase-positive), all cephalosporins, and all fluoroquinolones, but susceptible to colistin (MIC 0.5 mg/L) and sulbactam (MIC 4 mg/L). The fellow asks whether colistin monotherapy is appropriate given the limited options, or whether a combination regimen is preferred and why. Which of the following best reflects current evidence and pharmacological rationale for colistin use in this context?
A) Colistin monotherapy is preferred for pan-resistant Acinetobacter baumannii pneumonia because adding a second agent with a different mechanism creates an additive nephrotoxic burden that exceeds any benefit from antimicrobial synergy; the pharmacodynamic advantage of colistin monotherapy in achieving rapid membrane disruption outweighs the theoretical benefit of combination regimens
B) Colistin combination regimens are preferred over monotherapy for serious pan-resistant Acinetobacter baumannii infections; colistin monotherapy is associated with high rates of clinical failure and on-therapy resistance emergence due to heteroresistance — the presence of colistin-resistant subpopulations at baseline that are selectively amplified during monotherapy; combination with a carbapenem (despite the resistant MIC) or sulbactam may provide synergy and reduce resistance emergence
C) Colistin should not be used for pulmonary infections because its large molecular size and highly cationic structure prevent it from achieving adequate alveolar epithelial lining fluid concentrations when administered intravenously; inhaled colistin reaches adequate pulmonary concentrations but is contraindicated in patients with liver failure due to hepatic accumulation of the prodrug colistimethate
D) Sulbactam monotherapy is superior to colistin for OXA-23-producing Acinetobacter baumannii because sulbactam has dual activity — beta-lactamase inhibition that suppresses OXA-23 combined with direct PBP inhibitory activity against Acinetobacter; the colistin susceptibility result is less clinically relevant because colistin-resistant mutants emerge within 48-72 hours of initiation in all Acinetobacter pneumonia patients regardless of initial MIC
E) The OXA-23 carbapenemase finding is clinically irrelevant to the colistin treatment decision because OXA-type carbapenemases do not interact with polymyxins in any way; the appropriate regimen is colistin alone at standard doses until susceptibility testing for rifampicin and minocycline returns, at which point a second agent can be added only if these agents show susceptibility
ANSWER: B
Rationale:
Option B is correct. Colistin monotherapy for serious pan-resistant Acinetobacter baumannii infections is associated with high rates of clinical failure and on-therapy resistance emergence, and combination regimens are generally preferred based on both in vitro synergy data and observational clinical evidence. A critical pharmacodynamic concern is heteroresistance: most A. baumannii clinical isolates contain subpopulations of colistin-resistant organisms at frequencies of 10^-6 or higher, even when the overall MIC indicates susceptibility. Colistin monotherapy exerts strong selective pressure that rapidly amplifies these pre-existing resistant subpopulations, converting a susceptible isolate to a resistant one during therapy — often within days. Combining colistin with a second agent such as a carbapenem (even at above-MIC concentrations, carbapenem may contribute to synergistic killing through membrane disruption synergy with colistin), sulbactam (which has direct PBP-inhibitory activity against Acinetobacter independent of its beta-lactamase inhibitor role), or rifampicin may reduce this resistance emergence and improve outcomes. The evidence base is largely observational for combination therapy, but most infectious disease guidelines endorse combination approaches for pan-resistant Acinetobacter infections given the very high mortality of monotherapy failure.
Option A: Option A is incorrect because the nephrotoxicity argument against combination therapy does not outweigh the clinical benefit; colistin's nephrotoxicity risk is real but manageable, and the mortality benefit from combination over monotherapy in pan-resistant Acinetobacter infections is the dominant clinical consideration.
Option C: Option C is incorrect because colistin (as colistimethate sodium) is a prodrug that achieves systemic distribution when administered intravenously, and intravenous colistin is the standard administration route for systemic infections including pneumonia; inhaled colistin is used as adjunctive therapy but is not the only route, and hepatic failure does not specifically contraindicate colistimethate.
Option D: Option D is incorrect because sulbactam is a useful option against Acinetobacter with its direct PBP inhibitory activity, but the claim that colistin-resistant mutants emerge universally within 48-72 hours in all patients regardless of initial MIC overstates the resistance emergence risk as an absolute phenomenon and incorrectly frames sulbactam as universally superior to colistin.
Option E: Option E is incorrect because OXA-23 status is relevant to the overall treatment strategy — carbapenem options are excluded by this finding — even though OXA carbapenemases do not directly affect colistin activity; dismissing molecular testing results as "clinically irrelevant" and deferring all combination decisions pending rifampicin and minocycline testing is not appropriate management for a critically ill patient with pan-resistant bacteremia.
15. A 38-year-old otherwise healthy woman presents with dysuria, frequency, and urinalysis showing pyuria. Urine culture grows 100,000 CFU/mL of E. coli resistant to ampicillin, trimethoprim-sulfamethoxazole (TMP-SMX), and ciprofloxacin, but susceptible to nitrofurantoin, fosfomycin, and meropenem. She is hemodynamically stable with no fever, no costovertebral angle tenderness, and two blood cultures drawn in the emergency department are pending. The intern asks whether a carbapenem is required given the ESBL-producing phenotype on the susceptibility report. Which of the following best characterizes the appropriate management approach?
A) Meropenem is required for any ESBL-producing E. coli infection regardless of clinical severity, because the ESBL phenotype predicts treatment failure with all non-carbapenem agents including nitrofurantoin and fosfomycin; these agents appear susceptible on testing but ESBL enzyme overexpression at high in vivo bacterial densities has been shown to generate metabolic cross-resistance to non-beta-lactam urinary agents through a shared nitroreductase pathway disruption
B) The pending blood culture results must be finalized before initiating any antibiotic therapy; because ESBL-producing E. coli cystitis has a high rate of concurrent bacteremia, initiating oral nitrofurantoin or fosfomycin before confirming blood culture negativity risks masking bacteremia with an agent that lacks systemic efficacy, and empiric meropenem should be started now and de-escalated if blood cultures remain negative at 48 hours
C) The ESBL susceptibility phenotype must first be confirmed by a reference laboratory using E-test methodology before any treatment decision is made; the initial susceptibility panel may not accurately identify ESBL production, and empirically treating with nitrofurantoin or fosfomycin before ESBL confirmation risks clinical failure and unnecessary antibiotic resistance amplification
D) Nitrofurantoin or fosfomycin is appropriate oral therapy for this uncomplicated ESBL-producing E. coli lower urinary tract infection; carbapenem-sparing oral agents that retain in vitro activity and achieve urinary concentrations well above the MIC are appropriate for uncomplicated cystitis regardless of ESBL status; carbapenem therapy is indicated if blood cultures return positive, given the documented risk of cephalosporin and BLBLI (beta-lactam/beta-lactamase inhibitor) clinical failure in ESBL-producing bacteremia
E) Ciprofloxacin should be used despite the reported resistance because the MIC for fluoroquinolone-resistant ESBL E. coli is reliably below the pharmacokinetic-pharmacodynamic target achievable with high-dose ciprofloxacin 750 mg twice daily; fluoroquinolone dose escalation overcomes QRDR-mediated resistance in uncomplicated cystitis because urinary concentrations exceed the MIC by more than 100-fold at this dose regardless of the in vitro resistance result
ANSWER: D
Rationale:
Option D is correct. ESBL-producing E. coli infections require carbapenem therapy for serious infections including bacteremia and pyelonephritis with bacteremia, but not for all clinical presentations. For uncomplicated lower urinary tract infection — cystitis without systemic features, fever, or bacteremia — the key question is whether the chosen agent achieves concentrations in the urine substantially above the MIC. Nitrofurantoin and fosfomycin are not beta-lactams and are not substrates for ESBL enzymes; both achieve high urinary concentrations and retain full in vitro activity against susceptible ESBL-producing E. coli. IDSA and ESCMID guidelines specifically endorse nitrofurantoin and fosfomycin as appropriate carbapenem-sparing options for uncomplicated ESBL-producing E. coli cystitis. The pending blood cultures are the critical decision branch: if positive, the clinical scenario shifts from uncomplicated cystitis to bacteremia with a urinary source, and the ESBL inoculum effect makes cephalosporin and BLBLI therapy unreliable, necessitating escalation to carbapenem-based therapy.
Option A: Option A is incorrect because nitrofurantoin and fosfomycin are not beta-lactams and are not substrates for ESBL enzymes; there is no established nitroreductase cross-resistance pathway linking ESBL overexpression to nitrofurantoin resistance, and guideline bodies have specifically endorsed these agents for ESBL cystitis.
Option B: Option B is incorrect because withholding appropriate antibiotic therapy for symptomatic cystitis pending 48-hour blood culture results is not appropriate management for an otherwise healthy patient with an uncomplicated presentation; empiric meropenem is not indicated for uncomplicated cystitis, and the rate of concurrent bacteremia in uncomplicated cystitis without systemic features does not justify empiric IV carbapenem initiation.
Option C: Option C is incorrect because E-test confirmation by a reference laboratory is not required before treating uncomplicated UTI; standard clinical laboratory susceptibility testing provides sufficient guidance, and deferring treatment for a symptomatic patient pending reference confirmation is not appropriate clinical practice.
Option E: Option E is incorrect because dose escalation does not reliably overcome QRDR-mediated fluoroquinolone resistance; the susceptibility report shows ciprofloxacin resistance, and the pharmacodynamic relationship for fluoroquinolones depends on AUC/MIC ratio — when the MIC is elevated due to QRDR mutations, dose escalation does not restore clinical efficacy in the way described.
16. An antibiotic stewardship team is reviewing antibiotic prescribing practices on a general medicine ward. They find that many patients with community-acquired pneumonia are receiving 10-14 days of antibiotics despite clinical guidelines recommending 5-day courses for mild-to-moderate CAP in patients who respond to therapy. The team explains that unnecessarily prolonged antibiotic courses contribute to resistance selection. A medical student asks how a few extra days of antibiotics in one patient contributes to a population-level resistance problem. Which of the following best explains the mechanistic link between unnecessary antibiotic duration and resistance amplification at the individual and population level?
A) Prolonged antibiotic exposure depletes the gut microbiome of all bacterial species including resistance gene reservoirs, paradoxically reducing the pool of transferable resistance genes available to pathogens; the resistance problem from prolonged antibiotics is therefore primarily immunological rather than microbiological — dysbiosis impairs immune priming and increases susceptibility to future resistant infections
B) Prolonged antibiotic courses are primarily harmful because they increase the peak serum concentration of the antibiotic on the final days of therapy, and higher concentrations on day 10-14 drive more QRDR mutations than are generated early in therapy when serum concentrations are still rising; shorter courses maintain concentrations in the bactericidal but non-mutagenic range
C) Every day of antibiotic therapy maintains selection pressure in the patient's gut, respiratory, and skin microbiomes — the largest reservoir of bacteria in the human body — favoring survival and replication of organisms with resistance determinants; prolonged courses extend this selective pressure beyond the period needed to achieve clinical cure, unnecessarily amplifying resistant subpopulations in the microbiome that can subsequently transfer resistance genes to pathogens or seed future infections; shorter courses consistent with clinical cure minimize this selection window
D) Prolonged antibiotic exposure causes bacteria to enter a viable-but-non-culturable (VBNC) state in which they upregulate horizontal gene transfer machinery as a stress response; the resistance problem from prolonged antibiotics specifically reflects VBNC organisms that transfer resistance plasmids at higher frequency than actively replicating bacteria and cannot be detected by standard cultures to guide de-escalation
E) The resistance problem from prolonged antibiotic courses is confined to the specific pathogen being treated; additional days of therapy selectively amplify resistant subpopulations of the index pathogen within the infected tissue and have no measurable effect on the commensal microbiome, which is protected from antibiotic exposure by the physical barrier properties of the mucosal epithelium
ANSWER: C
Rationale:
Option C is correct. The mechanistic link between antibiotic duration and resistance amplification operates primarily through selective pressure on the enormous microbial communities that colonize the human body — the gut, respiratory tract, urinary tract, and skin — which together contain far more bacteria than any site of active infection. Every day of antibiotic therapy maintains an ecological pressure that favors organisms with resistance determinants (whether intrinsic or acquired): susceptible organisms are killed or suppressed, while resistant organisms survive and replicate without competition, accumulating in the microbiome. This selection operates not only on the target pathogen but on the entire commensal community, which serves as a reservoir for resistance genes that can be transferred horizontally to pathogens later. When antibiotic exposure is prolonged beyond the period required for clinical cure, this selection window is extended unnecessarily, amplifying resistant microbiome communities in this patient and — through household transmission, healthcare contact, and environmental shedding — in their contacts and community. Shortening antibiotic courses to the minimum effective duration reduces the total selection window, is endorsed by IDSA guidelines for most infections with well-defined shorter course data, and is one of the most impactful individual-level stewardship interventions.
Option A: Option A is incorrect because prolonged antibiotics do not paradoxically reduce resistance gene reservoirs; antibiotic-induced dysbiosis reduces microbiome diversity but selects for resistant organisms within the depleted community, increasing rather than decreasing resistance gene prevalence in the patient's microbiome.
Option B: Option B is incorrect because peak serum concentration does not increase progressively with antibiotic course duration; pharmacokinetics reach steady-state typically within 5 half-lives of initiation, and prolonged courses at standard doses do not produce higher peak concentrations on later days, nor does a dose-dependent mutagenesis mechanism account for the population-level resistance problem from prolonged therapy.
Option D: Option D is incorrect because while VBNC states exist, they are not the primary mechanism explaining the resistance amplification risk from prolonged antibiotic courses; the dominant mechanism is ecological selection pressure on the microbiome, not stress-induced horizontal gene transfer by non-culturable organisms.
Option E: Option E is incorrect because antibiotic exposure has well-documented effects on the commensal microbiome; the mucosal epithelium does not prevent systemic antibiotics from reaching commensal bacteria in the gut and other colonized sites, and the resistance effects of antibiotic therapy on commensal communities are a central concern in both individual patient care and population-level antibiotic stewardship.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.